Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 29M | 2187.3% |
| Gross Profit | 29M | 2226.1% |
| Cost of Revenue | 210,000 | 596.7% |
| Operating expense | 25M | 7.4% |
| Net Income | 3.3M | 112.9% |
| EBITDA | 5.7M | 122.4% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 226M | 24.2% |
| Total Liabilities | 96M | 44.9% |
| Total Equity | 129M | 5.2% |
| Shares Outstanding | 364M | 0.4% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | 17M | 138.8% |
| Cash from investing | 15M | 61.8% |
| Cash from financing | -45M | 7767.1% |
EPS
Financial Highlights for Lexicon Pharmaceuticals in Q2 '25
Lexicon Pharmaceuticals reported a revenue of 29M, which is a 2187.3% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 29M, marking a 2226.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 210,000, a 596.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 25M, showing a -7.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 3.3M, showing a 112.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 5.7M, showing a 122.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Lexicon Pharmaceuticals with growth in revenue, gross profit, and net income.
